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Abstract: 
Objective: To screen for cognitive and behavioral impairment in people with 
amyotrophic lateral sclerosis (ALS) and controls with neuromuscular disease and to   
correlate these with clinical features. 
Methods: 108 people with ALS and 60 controls with other neuromuscular diseases 
were recruited and assessed with the Addenbrooke’s cognitive examination-III (ACE-
III), the Frontal assessment battery (FAB), and the executive function component of 
the Edinburgh cognitive and behavioral ALS screen (ECAS). The Amyotrophic 
lateral sclerosis-Frontotemporal dementia questionnaire (ALS- FTD-Q) and the Motor 
Neuron Disease Behavioral instrument (MiND-B) were administered to the caregivers 
of people with ALS. The prevalence of abnormalities was determined and correlated 
with clinical features and survival. In 37 people with ALS, serial studies were 
performed.  
Results:  The frequencies of cognitive impairment based on the ACE-III and FAB 
were 30.0% and 14.0%, in ALS and 11.7% and 3.3% in controls, respectively. Age 
and years of education influence the results of the ACE-III and ECAS executive 
function. In ALS, the frequencies of behavioral impairment based on ALS-FTD-Q 
and MiND-B were 32.1% and 39.4 %, respectively. There is significant correlation of 
ALS-FTD-Q and MiND-B with the ALSFRS-R score. ALS participants with 
cognitive impairment measured with ACE-III had significantly shorter survival time 
than those without. ALS participants with behavioral impairment measured with 
ALS-FTD-Q had worse prognosis than those without. No significant difference was 
found between the first two serial cognitive tests based on ACE-III and FAB by using 
generalized estimating equation. 
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Conclusion: There is a greater frequency of cognitive impairment in people with ALS   
than in patients with other neuromuscular diseases. The cognitive and behavioral tests 
are potential biomarkers of the prognosis of ALS. The results of cognitive tests are 
stable over 6 months and possibly longer.  
 
 
Keywords: Amyotrophic lateral sclerosis, cognitive impairment, behavioral 
impairment, survival, longitudinal study 
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Introduction 
         Amyotrophic lateral sclerosis is defined by progressive loss of upper and lower 
motor neurones [1] . Some people with ALS also have frontotemporal dementia (FTD) 
while others have lesser degrees of cognitive impairment [2]. Some of the overlap 
between ALS and FTD is associated with the presence of a C9orf72 gene mutation [3, 
4]. Different approaches have been used to study the frequency of cognitive 
impairment. Full neuropsychological testing is time-consuming. Therefore a variety 
of simple tools have been used to screen for cognitive impairment in ALS. These 
include Addenbrooke’s cognitive examination–III (ACE-III),  an updated version of 
the ACE-R [5-8], the Frontal assessment battery (FAB) [9-11], the Edinburgh 
cognitive and behavioral ALS screen (ECAS), which includes tests of social cognition,        
[12-16] and  the ALS cognitive behavioral screen (ALS CBS) [17]. Table 1 shows the 
elements tested in the different tools. Other scales have been developed to detect 
behavioral dysfunction in ALS [18, 19]. These include the Amyotrophic lateral 
sclerosis-Frontotemporal dementia questionnaire (ALS-FTD-Q) and the Motor 
Neurone Disease Behavioural instrument (MiND-B), which are administered to carers.  
           With such screening tools, the incidence of the cognitive impairment in ALS 
ranges from 30 to 75% [20-23] and the rate of behavioral impairment ranges from 14% 
to 40% [12, 23-25] (Table 2). 
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Table 1 Summary of domains tested by screening tools used in ALS 
Cognitive Domain 
 
ACE-III FAB ECAS ALS CBS 
Attention  
 
Yes* No No Yes 
Memory  
 
Yes* No Yes  No 
Verbal fluency  
 
Yes* Yes* Yes Yes 
Language or conceptualization  Yes* Yes* Yes No 
Visuospatial 
 
Yes* No No No 
Prehension behaviour 
 
No Yes* No No 
Executive function 
 
No Yes* Yes* Yes 
Social cognition (as part of 
executive function) 
 
No No Yes* No 
ALS CBS: ALS cognitive behavioural screen  
ECAS: Edinburgh cognitive and behavioral ALS screen                       
ACE-R: Addenbrooke’s cognitive examination revised  
FAB: Frontal assessment battery     
*Test used in the present study 
ACCEPTED MANUSCRIPT
AC
CE
PTE
D M
AN
US
CR
IPT
6 
 
Table 2 Summary of the recent papers in cognitive and behavioral impairment 
Measurement Country/year No of 
patients 
Percentage of 
cognitive 
impairment 
Percentage of 
behavioral 
impairment 
Reference 
ALS CBS USA/2016 274 54% 14% Murphy et al.[23] 
ECAS China/2016 84 36 % 27 % Ye et al.[13] 
ECAS Italy/2016 107 37% 54% Poletti et al.[16] 
ALS CBS USA/2015 86 62% 37% Bock et al.[26] 
FAB Greece/2015 34 50% N/A Nidos et al.[27] 
ALS CBS Spain/2015 50 46% 18% Turon-sans et al.[28] 
ACE-R China/2014 145 30% N/A Wei et al.[22] 
FAB  Canada/2014 44 21%  N/A Osborne et al.[29] 
MoCA Canada/2014 39 53% N/A Osborne et al.[29] 
FAB and FBI China/2014 126 32% 46% Wei et al.[30] 
ECAS Germany/2014 136 22% 30% Lule et al.[14] 
FAB USA/2009 16 50% N/A Oskarsson et al.[31] 
ALS CBS: ALS cognitive behavioral screen ECAS: Edinburgh cognitive and behavioral ALS screen  
ACE-R: Addenbrooke’s cognitive examination revised FAB: Frontal assessment battery 
FBI: Frontal behavior inventory MoCA: Montreal cognitive assessment 
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          Current evidence suggest that some people with ALS have cognitive and 
behavioral impairment, and others do not. The cause of this is unclear. As already 
mentioned, carriage of a repeat expansion in C9orf72 is a cause of cognitive 
impairment in ALS, but there could be other factors. There have been attempts to 
determine whether clinical features are correlated with the presence of cognitive and 
behavioral testing. Some studies have found cognitive impairment to be more common 
in people with bulbar onset than limb onset of ALS [32].  However, other studies 
suggest that site of onset has no influence on the presence of cognitive impairment [33-
35]. Therefore further information is required.  
         There have also been studies of whether the presence of cognitive or behavioral 
impairment affects prognosis, as might be the case if the presence of cognitive 
impairment indicates more severe or widespread disease. Some studies have suggested 
that the presence of cognitive impairment [36] or behavioral abnormality is associated 
with worse prognosis [37]. However, other studies suggest that cognitive impairment 
has no influence on survival [35]. Therefore further information is required. 
         Another possibility is that cognitive impairment, and other extramotor features of 
ALS, might develop in all people with ALS over time, as disease spreads more widely 
[38]. If this were the case, cognitive impairment would correlate with disease severity, 
but there is little information about this. There is conflicting information about whether 
there is later development of cognitive impairment in patients who are cognitively 
normal at onset of ALS [39-42] . Further information is required about this issue as 
well.  
         The first aim of the present study is to measure cognitive and behavioral 
impairment in the ALS patients by using 5 different  clinic based questionnaires (ACE-
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III, FAB, the executive component of the ECAS, ALS-FTD-Q, MiND-B), and to 
compare with controls with other neuromuscular disease, with the hypothesis that 
cognitive and behavioral impairment is greater than in neuromuscular disease. The 
rationale for this study is that people with neurological disorders would be more 
suitable controls than healthy people, because people with neuromuscular disease 
attending the same department would have similar background and experience many of 
the same difficulties as people with ALS attending our clinic.  
        The second aim is to determine whether the presence of cognitive and behavioral 
impairment is related to the clinical features of the patient,  to test the hypothesis, based 
on previous reports, that bulbar onset of ALS is correlated with cognitive impairment, 
and that age and education would influence cognition in ALS, as is the case in healthy 
people [43] and that cognitive impairment is related to disease severity as would be the 
case if cognitive impairment occurs with more severe and widespread disease. The 
rationale for this was to provide further information about this unresolved issue. The 
third aim is to evaluate the effects of cognitive and behavioral impairment on survival, 
with the hypothesis that the presence of cognitive impairment indicates more severe 
and wide spread disease, and would be expected to worsen prognosis. 
         The final aim is to determine if there is deterioration in cognition over time. The 
reasoning behind this study was to investigate whether patients who are cognitively 
normal at onset develop dysfunction over time, or whether ALS can be divided into 
people with cognitive issues and people without cognitive issues. 
Methodology 
1.1 Subjects:          
        People with probable or definite ALS [1] were recruited from the 
multidisciplinary MND clinic at Royal Brisbane and Women’s Hospital (RBWH). The 
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caregivers of the patients were also asked to complete questionnaires about the 
behaviour of the person with ALS. There was no systematic genetic screening; 
however, 5 people with ALS are known to have causative mutations (3 with C9orf72 
repeat expansions, one with transactive response DNA binding protein (TARDBP) 
mutation and one with superoxide dismutase 1(SOD1) mutation). Of 81 people with 
ALS for whom there was information about the family history of ALS, 10 had familial 
ALS. Information about a family history of dementia was available from 54 people 
with ALS, of whom 10 had a positive family history. 
      The controls were people with neuromuscular diseases with no evidence of disease 
of the central nervous system. Informed written consent was obtained from all 
participants and caregivers. This research project was approved by the RBWH ethics 
committee (HREC/15/QRBW/68). 
1.2 Clinical details:  
        The age, gender, the date of onset of symptoms and the site of onset of symptoms 
were recorded. The revised ALS Functional Rating Scale (ALS-FRS-R) [44] was 
recorded at each visit. When applicable, the date of death was recorded and the length 
of survival from onset of disease to death or censoring was calculated. 
1.3 Cognitive and behavioral tests 
         All participants were tested with the ACE-III, which has a maximum possible 
score of 100. A score of less than 88 was defined as possible cognitive impairment [45]. 
The FAB, with a maximum possible score of 18, was also administered to all 
participants. A score of less than 12 was regarded as high possibility of cognitive 
impairment [10]. 
         The executive function section of the ECAS (which includes reverse digit span, 
alternation, sentence completion and social cognition) was added to the testing panel 
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later in the study. It was administered to 41 people with ALS and 30 controls. The 
cutoff value for cognitive impairment is 33 of 48 [12].  Some people with ALS were 
unable to complete the tests due to physical disability. This was the case for 19 people 
for the ACE-III and for 3 for the FAB. To deal with this, we calculated the percentage 
of correct responses of the items that were tested, and then estimated the final score as 
this percentage of the total possible.  This approach is an approximation, but has been 
used by others in this field [46].  
        Carers were tested with ALS-FTD-Q and MiND-B to detect behavioral 
abnormalities.  The MiND-B evaluates disinhibition, apathy and stereotypical 
behaviour. The cutoff values for ALS-FTD-Q and MiND-B were 29 and 34, 
respectively [18, 19]. The relationship between the carer and the person with ALS was 
also recorded.   
   To evaluate any changes over time, serial cognitive tests, at intervals of 6 months 
or more, were obtained from 37 patients.  
1.4 Statistical analysis 
        Statistical analysis was performed with SPSS 20 software. To compare groups, 
ANOVA was used, if the variables were normally distributed. Otherwise, the data were 
compared with the Mann-Whitney U test for two independent groups.  To compare the 
proportions of groups, the χ2 test was used. To determine whether cognitive and 
behavioral function were influenced by clinical features, multiple logistic regression 
was used to evaluate the effects of age, gender, disease duration at the time of testing, 
years of education, site of onset and relationship of the carer to the person with ALS, 
To determine whether there was an association between disease severity measured by 
ALSFRS-R and scores of cognitive and behavioral testing, we used the Spearman rank 
test. To assess the effects of cognition and behavior on survival, Kaplan-Meier curve 
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and log rank test were utilized to compare survival between patients with normal and 
those with abnormal results. A Cox proportional regression model was used to report 
the hazard ratio and 95% confidence interval for each cofactor affecting prognosis. A 
generalized estimating equation model was used to test the longitudinal data. The 
model based estimator was chosen in the covariance matrix. Unstructured working 
correlation matrix was selected. P<0.05 was considered as significant.  
Results 
1.1 Clinical features 
      Clinical features of patients and controls, and numbers of participants for each test, 
are given in Table 3. The diagnoses of the people with neuromuscular disease are given 
in Error! Reference source not found.. 
Table 3 Clinical features of the patients and controls 
 ALS Other 
neuromuscular 
disease 
P 
value# 
Total number  
 
108 60  
Males: females 
 
68/40 35/25 0.5550 
Age (mean, SD) 
 
63.8±10.6 62.3±12.1 0.4025 
Years of school  
education( median, range)  
11 (5,30) 10 (7,19) 0.1160 
No tested with ALSFRS-R  88 N/A  
No tested  with ACE-III 
 
108  60  
No needing adjustment of 
ACE-III* 
19 N/A  
No tested with FAB 
 
 
108  60  
No needing adjusting of 
FAB* 
3 N/A  
No with executive section 
of ECAS 
41 30  
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No tested with ALS-FTD-
Q 
 
84 N/A  
No tested with MiND-B 
 
66 N/A  
     *In these patients, some test items were omitted and the score was adjusted 
 
 
 
                                                             Table 4 Diagnoses of controls 
Disease category No  
Peripheral nerve disorder  
Idiopathic neuropathy 15 
Carpel tunnel syndrome 2 
Diabetic neuropathy 2 
Guillain–Barré syndrome 1 
Pelvic neurofibroma 1 
Charcot-Marie-Tooth disease 5 
Anterior interosseous syndrome 1 
Anti Myelin-associated glycoprotein (MAG) neuropathy 1 
Brachial plexus injury 1 
Cramp fasciculation syndrome 1 
Chronic inflammatory demyelinating polyneuropathy 3 
Schwannoma posterior tibial nerve 1 
Small fibre neuropathy 2 
Trigeminal neuropathy 1 
Multifocal motor neuropathy 2 
Muscle disease  
Mitochondrial myopathy 2 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
13 
 
Pompe disease 1 
Inclusion body myositis 3 
Facioscapulohumeral muscular dystrophy 5 
Myopathy 1 
Idiopathic hyperCKemia 1 
Anterior horn cell non-ALS  
Spinal muscular atrophy type 2 1 
Myasthenia gravis 7 
Total 60 
 
1.2 What is the prevalence of cognitive and behavioral impairment?  
         The frequency distributions of ACE-III and FAB scores in disease controls and 
ALS patients are shown in Figure 1. The cognitive test scores are summarized in Table 
5. There are significant differences in total CE-III, ACE-III attention and language 
scores and FAB total score between the groups. There were no significant differences 
in the other components of the ACE-III or in the executive section of the ECAS.  The 
percentages of each group with cognitive impairment are shown in Table 6. Between 
people with ALS and controls there is a significant difference in the percentage with 
abnormal results of ACE-III and FAB. However, no significant differences were found 
between the two groups in the scores of ECAS executive function and social cognition.  
           Of the patients with known causative genes, one with C9orf72 repeat expansion 
had normal cognitive function, and the other patients (2 with C9orf72 repeat 
expansions, one with TARDBP mutation and one with SOD1 mutation) had cognitive 
impairment, defined as abnormal result on ACE-III testing.  
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Table 5  Results of cognitive tests 
Test ALS  Controls P value# 
ACE-III total score ( median 
range) 
92 (60-100) 94 (79-100) P=0.023* 
        Attention score ( mean SD) 16.4±1.9 17.2±1.0 P=0.003** 
        Memory score ( mean SD) 23.1±2.9 23.6±2.0 P=0.552 
        Fluency score ( mean SD) 10.9±3.0 11.6±2.2 P=0.343 
        Language score ( mean SD) 24.5±2.1 25.2±1.0 P=0.024* 
        Visuospatial score ( mean 
SD) 
15.3±1.1 15.5±0.9 P=0.305 
FAB total score ( median range) 16(6-18) 17(12-18) P=0.004** 
ECAS executive score ( median 
range) 
40(17-45) 40(26-47) P=0.487 
        Social cognition subsection 
score(median range) 
12(0-12) 12(0-12) P=0.192 
  *: P<0.05 **: P<0.01 # Mann-Whitney U test was used. 
                   
Table 6 Percentage of people with cognitive impairment  
Test  Cut off value for 
abnormality 
ALS 
percent 
abnormal   
Controls 
percent 
abnormal 
P value# 
ACE-III  ≤88 30.0% 11.7% P=0.013* 
FAB  ≤12 14.0% 3.3% P=0.033* 
ECAS executive 
function 
≤33 22.0% 16.7% P=0.802 
      *: P<0.05, # χ2 test was used 
   
       The behavioral test scores are shown in Table 7. The frequencies of behavioral 
impairment measured by ALS-FTD-Q and MiND-B are 32.1% and 39.4% respectively. 
The rates of disinhibition, apathy and stereotypical behaviour are 9.1%, 21.2% and 
7.6%, respectively. 
Table 7  Results of behavioral testing 
Test  Cut off value for 
abnormality 
ALS  
(median, range) 
Percentage with 
abnormality 
ALS-FTD-Q score ≥22 15(0-57) 32.1% 
MiND-B total score  <34 34(14-36) 39.4% 
          Disinhibition  <13 16(8-16) 9.1% 
          Apathy  <9 11(4-12) 21.2% 
          Stereotypical 
behaviour  
<5 8(2-8) 7.6% 
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1.3 Correlation between cognitive and behavioral impairment and other clinical 
features 
        Multiple logistic regression analysis was used to investigate whether age, gender, 
years of education, disease duration at the time of testing and site of onset influenced 
the results of the ACE-III, FAB and ECAS cognitive tests. The detailed results are 
given in Supplementary 1 file. For ACE-III, age and years of education influence the   
results. One year increase in age can increase hazard odds of cognitive impairment on 
ACE-III testing by 5.3%, while one year increase in the years of school education can 
reduce hazard odds of cognitive impairment by 27%. There was no effect of site of 
onset, disease duration and gender on the results of ACE-III testing.   
        For ECAS executive function, one year increase in education can decrease 26% of 
ratio of cognitive impairment. The other clinical factors did not affect the test result. 
        For FAB, the site of onset affected the results. Compared with lower limb onset, 
people with bulbar onset of ALS had 61% less hazard odds ratio of cognitive 
impairment. There is no significant correlation between other variables and cognitive 
impairment as measured by FAB. 
       The effects of the clinical variables in ALS-FTD-Q and MiND-B are also 
presented in Supplementary 1 file.  Age, gender disease duration and the relationship 
of the carer to the person with ALS have no significant effect on behavioral 
impairment. 
       The results of ACE-III and FAB in patients with and without positive family 
history of ALS and dementia are summarized in Supplementary 1 file. The presence of 
a positive family history of ALS or dementia had no significant effect on the cognitive 
impairment based on ACE-III and FAB results.  
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         We assessed the correlation between disease severity measured by ALSFRS-R 
and cognitive function measured by ACE-III, FAB and ECAS by using Spearman 
correlation tests (Supplementary 2 file). There was no significant correlation. This 
indicates that cognition does not worsen as the disease becomes more severe. 
         We also tested the relationship between disease severity and behavioral testing. 
The Spearman correlation tests between ALS-FTD-Q or MiND-B and ALSFRS-R 
score are shown in Figure 2. There is a significant negative relationship between ALS-
FTD-Q and ALSFRS-R score. There is a significant positive association between 
MiND-B and ALSFRS-R score. This indicates that behavioral impairment becomes 
worse as disease becomes more advanced. 
1.4 Correlation with the survival time in cognitive and behavioral tests 
            We then investigated the effect on survival of cognitive and behavioral 
impairment measured by ACE-III, FAB, ALS-FTD-Q and MiND-B. The results for 
ACE-III, FAB and ALS-FTD-Q are shown in Figure 3.  We first plotted Kaplan Meier 
survival curves. The survival curve of MiND-B is presented in Supplementary 3 file. 
There is a significant effect on survival of cognitive and behavioral impairment 
measured by ACE-III and ALS-FTD-Q. For cognitive impairment measured by FAB, 
there was an apparent effect, but this was not statistically significant. For behavioral 
impairment measured by MiND-B, there was no apparent effect on survival.   
              We then performed Cox regression analysis of the effects of cognitive and 
behavioral testing and other clinical features on survival. The Cox regression models of 
ACE-III, FAB, ALS-FTD-Q and MiND-B which included age, gender and site of onset 
are shown in Supplementary 3 file.   
               Patients with cognitive impairment defined by performance on ACE-III had 
significant shorter survival than the patients without cognitive impairment (P=0.0276), 
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with no additional effect of age or gender.  There was no significant effect on survival 
time based on FAB (P=0.1746).  The site of onset affected the survival time of patients 
with bulbar onset leading to a significant increase in comparison with the patients with 
lower limb onset after adjusting the age, gender and cognitive impairment ( P=0.045). 
             Patients with behavioral impairment based on ALS-FTD-Q had significantly 
shorter survival than the patients without (P=0.0054). There are no significant 
differences between survival time of patients with and without behavioral impairment 
assessed with MiND-B (P= 0.5685). The Cox regression model of MiND-B illustrates 
that other variables including gender, age, disinhibition, apathy and stereotypical 
behaviour do not impact the survival time of the patients.       
1.5 The longitudinal study of cognition 
               We performed a longitudinal study of 37 people with ALS. This was to 
determine whether cognitive impairment develops over time in people who are 
cognitively normal on first testing. The longitudinal curves for 37 patients with 
different sites of onset based on ACE-III and FAB are presented in Figure 4 and Figure 
5 respectively. The five domains of ACE-III serial tests results are shown in 
Supplementary 4 file. Some patients show a decline with serial testing, but most do not. 
There were fewer tests for the third and fourth time points due to death or advanced 
progression of the patients.   
               For statistical analysis, we used generalized estimating equations for the first 
two tests of ACE-III and FAB (Supplementary 4 file). The GEE analysis for ACE-III 
found that there was no significant difference between the first two consecutive tests 
(P=0.080). However, patients with bulbar onset of ALS have 3.25 higher ACE-III 
scores than the patients with lower limb onset over the time course (P=0.033).  
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              The GEE analysis for FAB found no significant difference between the first 
two serial tests (P=1.00). For FAB, the site of onset did not affect the results of FAB 
performance over time (P=0.190).   
Discussion 
             This study assessed cognition and behaviour in people with ALS by using 
simple clinic based testing. As comparison we used people with neuromuscular disease. 
in our cohort, the prevalence of cognitive impairment was approximately 30% and 14% 
based on ACE-III and FAB, respectively This is similar to the rates of cognitive 
impairment found in previous studies [13, 16] (Table 2). The prevalence of behavioral 
impairment in our cohort is also just over 30% and approximately 40% based on ALS-
FTD-Q and MiND-B. This is slightly less than that found by others [16, 30] (Table 2). 
            Previous studies compared people with ALS with normal healthy controls [12, 
24] or had no controls. Our controls came from the same population as the people with 
ALS. None of the controls had evidence of disease of central nervous system, although 
two had mitochondrial myopathy, which could indicate a multi-system disorder. Both 
the average scores and the frequency of cognitive impairment were significantly 
different between the groups. In the ACE-III subdomains, significant differences were 
found in attention and language.  Our study did not find fluency difference between the 
two groups, in contrast to previous studies that compared ALS patients with healthy 
controls [47, 48].  We note that the tasks and scoring of fluency vary among the 
different tools, reducing the ability to compare results. 
         We used multiple logistic regression analysis to investigate factors that influence 
the development of cognitive or behavioural impairment in ALS.  We found that age 
and years of education affect the cognition measured by ACE-III.  This is unsurprising 
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as age and years of education are known to affect cognitive performance in the healthy 
population [43] and to reduce the risk of dementia [49]. Age and lower levels of 
education have been observed in several previous ALS studies as risk factors for 
cognitive impairment  [13, 21, 50], although others found no significant effect of these 
factors [35, 51, 52]. Using age corrected or education level corrected scoring guide 
would be desirable in future studies of cognition in ALS.  
          Previously, some studies have found that people with bulbar onset of ALS are 
more likely to have cognitive impairment than those with spinal onset [39, 53, 54], but 
others do not [33, 35, 55].  In our study, the site of onset had no effect of the presence 
of cognitive impairment as determined by the ACE-III, but site of onset influenced 
cognitive impairment based on FAB logistic regression results. In our cohort, the 
bulbar onset patients had decreased ratio of cognitive impairment and longer survival 
in the Cox regression model. This needs to be studied further. 
          In our cohort, the patients with cognitive or behavioral impairment based on 
ACE-III and ALS-FTD-Q had worse prognosis than the ones without. This is 
consistent with some previous studies [56, 57] but contrary to other studies [35, 58].  In 
our study, stereotypical behaviour, apathy, and disinhibition do not predict the survival 
of ALS patients, which is consistent with one previous study using the same scale [59]. 
However another study found that the apathy measured with the revised version of the 
Cambridge behavioral inventory (CBI-R) is good indicator of survival [60]. 
Classifying the patients into different level of cognitive and behavioral impairment 
could be better than using cutoff value in predicting the prognosis. A possible 
explanation for the worse prognosis of patients with cognitive impairment is that they 
have a disease that is more widespread and extensive than those with only motor 
symptoms. Another possibility is that those with cognitive impairment have different 
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causative genes than those without. The most prominent gene that causes ALS with 
cognitive impairment is C9orf72 [3, 4], but there are others such as TARDBP and 
fused in sarcoma (FUS) [61, 62].               
           In our longitudinal study, only a limited number of people had more than two 
tests. Because of variability in attendance at the clinic, the interval between two 
consecutive time points ranges from 6 months to 33 months. Therefore we used a 
generalized estimating equation (GEE) to investigate whether there is difference 
between first two serial tests. The GEE statistical model is very robust to abnormal 
distributions, missing data and heterogeneity in timing of measurement. No significant 
difference was found between the first two visits in both ACE-III and FAB, which 
suggests that the cognitive test performance is relatively stable, and these patients who 
are cognitively normal at first testing will remain so over time. However, more people 
with ALS are needed at later time points to clarify this. 
        Previous studies showed conflicting results. One study found that in bulbar onset 
patients, cognitive impairment was progressive over time [39], another found that 37% 
of patients developed cognitive deficit over a six month follow-up period [40], and 
another found that cognitive impairment was greater at the later stages of disease, 
when only 14% of patients had normal cognition [41], thus providing evidence that 
cognition is progressively affected in ALS. The previous serial studies of cognition are 
summarised in Table 8. If there were a progressive deterioration of cognition over time, 
this could be due to the spread of pathology from motor regions to other regions, 
through prion- like spread, as has recently been proposed [63]. However, the finding 
that some patients have cognitive impairment at presentation while others remain 
cognitively normal throughout disease would be more consistent with ALS being a 
heterogeneous disease [38, 64]. 
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       One weakness of this paper is that we have only limited genotyping. Another 
weakness is that we used simple screening tools that may not have detected subtle 
deficits. However, the tools that we have used are available for use in ALS clinics and 
provide evidence that some patients with ALS have cognitive impairment, which is a 
poor prognostic marker, that patients who are cognitively normal at onset show little 
evidence of deterioration over 6 months and possibly longer, and that age and 
education are risk factors for cognitive impairment in ALS. 
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Table 8 Summary of longitudinal studies of cognition in ALS 
Study Number  Results 
M.J. Strong et al. [34] 8 Cognitive impairment in the patients with bulbar onset but with limb-onset 
appeared to progress over the time course. 
K.M. Robinson et al. [65] 19 7 of 19 patients had a decline of cognition over time. 
F.Trojs et al. [41] 74 Cognitive impairment was more serious in the advanced stage of ALS. 
S.Abrahams et al. [66] 20 No evidence of deterioration of cognition over time. 
E.Kasper et al. [42] 93 No significant decline in executive function over time. 
M.Kilani et al. [67] 18 No decline in cognitive function over 12 months 
M.Elamin et al. [68] 98 for  the second visit 
48 for  the third visit 
Cognitive function declined faster in patients who were cognitively impaired at 
the first visit. 
H.Schreiber et al. [69] 52 Cognitive deficits did not substantially decline on follow-up. 
 
The list and the captions of Figures 
1. Figure 1: Frequency distribution of ACE-III and FAB score in ALS and controls. A: Frequency distribution of ACE-III in ALS patients B: 
Frequency distribution of FAB in ALS patients. C: Frequency distribution of ACE-III in disease control D: Frequency distribution of FAB in 
disease control. 
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2. Figure 2:  Correlation of behavioural testing with disease severity. A: ALS-FTD-Q correlation with ALSFRS-R. B: MiND-B correlation with 
ALSFRS-R. Significant negative correlation was found between ALS-FTD-Q score and ALSFRS-R score (P=0.0068). Significant positive 
correlation was found between MiND-B score and ALSFRS-R score (P=0.02). The solid red line and red curve line are the simple linear 
regression and its 95% confidence interval, respectively. 
3. Figure 3: Survival curve of ACE-III, FAB and ALS-FTD-Q. A:  Kaplan Meier survival curve of ACE-III   B: Kaplan Meier survival curve of 
FAB C: Kaplan Meier survival curve of ALS-FTD-Q. 
4. Figure 4: ACE-III longitudinal results in three different site of onset. The longitudinal curves were plotted in every patient according to 
different site of onset. 
5. Figure 5: FAB longitudinal results in three different site of onset. The longitudinal curves were plotted in every patient according to different 
site of onset. 
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Highlights 
 Comparison of cognitive and behavioral impairment between ALS patients and 
patients with neuromuscular disease. 
 Multiple cognitive and behavioral tests were used in this study. 
 Longitudinal study was done in the cognitive tests of ALS patients.  
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